Sales & Marketing

The hard work being done by the industry to prove its commitment to patients and better health is being hampered by its reputation of unreliability

With Exprience and A new means of measuring impact on patient behavior, branders have never been in a better position to make their strategies work

Sometimes looking back is a way to look forward

Build it and they will come. But how do you make them stay?

A win-win marketing strategy that illuminates, educates, and promotes at the same

New search engine gives consumers the ability to manage all their health needs from a central location--and offers pharma the opportunity to reach new patients through targeted search ads

These are challenging times for senior operations executives who support sales, marketing, and managed markets. The pipeline shortfall, drug-approval delays, and increasing regulatory complexity have squeezed budgets while raising revenue targets. The Medicare Modernization Act (MMA) has caused some of the most far-reaching changes in the sales and marketing landscape, as government purchasing power creates both new opportunities and greater restrictions. In addition, traditional modes of selling have saturated the market, and the sales model the industry knows and loves is no longer so effective.

Physicians are using the Internet for much more than requesting an occasional journal article. But do they visit the brand.com sites? Yes, and at predictable times, according to ePharma Physician, a new study from Manhattan Research. Yet not all drug sites cater to docs' needs. What can pharma marketers learn from the sites that do get docs to log on? Pharm Exec spoke with Mark Bard, president of Manhattan Research, to find out.

For years, advertising agencies have been coaxing people into back rooms at malls to review ads in exchange for a couple of dollars or a lotto ticket. Although this method of gauging ad effectiveness is useful for gathering thoughts about whether an advertisement is liked or disliked by a reader, it doesn't convey the whole story to the ad agency. Marketers want to know things like: Did you read the copy first or look at the photo? Are you distracted by a particular color? How obvious is the risk information? Does this ad have stopping power? Plus, with the mall approach, agencies must factor in the reality that many focus group participants just give the answers marketers want to hear and collect their cash.

Very few drugs live forever. Barring remarkable scientific advances and radical market dynamics, most drugs hit old age-and sharply declining sales-several years before their patent expires. But some drugs go out with a bang, not a whimper.

You have to admit: Mark McClellan, MD, has quite a resumé. But after you've been the commissioner of FDA and the administrator of the Centers for Medicare and Medicaid Services (CMS), what comes next?

If you've been thinking of online video as a toy or, worse yet, as something that's going to happen at some point in the future, let me offer you a picture: Me, a target pharma customer, on the elliptical machine at the gym, watching, no, not CNN or Katie Couric, but "Nephrology Consult 101, Unusual Causes of Renal Failure" and "Internal Jugular Central Line Placement," a pair of free video podcasts I downloaded from the Yale School of Medicine.

Search engine giant says industry lags behind on e-marketing

From pamphlets to posters to informational magazines, doctors' offices are teeming with direct-to-patient promotions, and patients are starting to overlook them. To cut through the clutter, one healthcare-technology company created a device that replaces the common intake clipboard with a digital pad that collects patient information and responds with branded information.

A study of doctors uncovers the hard facts behind what professional sales strategies work

For the sixth year in a row, Pharm Exec invites Professor Bill Trombetta of St. Joseph’s University to analyze the pharma industry's financial performance with a battery of business metrics, old and new. The highlights: Genentech pulls ahead of its longtime rival, Amgen. Forest delivers another strong performance, despite dropping revenue. Schering-Plough is building enterprise value. Biogen Idec racks up a stellar profit margin. And Merck? Well, Merck is back, baby. And the winner is…

Many see Vioxx and Avandia as clear signs that the drug safety system has failed. As soon as reports of these drugs' adverse events began to flood the media, consumers-and Congress-demanded to know: "Why didn't we know sooner?"

For pharma marketers, understanding the on-demand opportunity starts with recognizing that customers are, in many ways, ahead of the industry

Pharma surfaces on MySpace

Novartis' Zelnorm is back, but only through a restricted-access program.

Mel Sokotch has seen his share of consumer advertising, having worked in the business for nearly 30 years. He's done time at Foote Cone & Belding and Grey Advertising, and he's handled campaigns for Merck, Pfizer, and Eli Lilly. Most recently, Sokotch penned Shortcuts to the Obvious, a how-to book documenting common marketing mistakes and the ways in which agencies can better position ads. The book is geared toward general consumer advertising, but it includes numerous pharma examples. Pharm Exec caught up with Sokotch to learn more about what marketers can do to build better campaigns.

A new class of scales that can help capture drug effects-not necessarily disease impacts, as quality-of-life instruments currently do-will likely be needed to identify the meaning of the drug's benefits to patients

Brand essence is the result of a mixture of empirical facts, brand personality, functional benefits, and feelings that leads to the differentiating brand idea

Avandia's market share erosion was magnified further by the almost complete absence of new prescriptions being switched to Avandia from its competitors. In the weeks before the event, Avandia accounted for more than 20 percent of all switches by primary care physicians

Spending expected to increase mildly in the short term

In the wake of a high-profile death from counterfeit drugs, the industry reacts

Personalized health communication enables marketers to vary the messages they deliver, and it increases their ability to motivate different patients to act

Although pricey, serialization with RFID is expected to reduce logistical errors and address some aspects of supply chain security

Though it may sound paradoxical, the most effective deployment of a patient-feedback program is within a pharmaceutical brand's professional promotions

We'll see a more coordinated, worldwide platform not just for marketing, but for R&D and regulatory because of the harmonization that is slowly coming, primarily between Japan, Europe, and the United States